prescriber.co.uk ■ PRESCRIBING IN PRACTICE R ecent estimates put the prevalence of familial hypercholesterolaemia (FH) in the UK in the region of 1 in 250 to 1 in 360 people, resulting in upwards of 150,000 affected individuals. 1, 2 FH is characterised by a significant lifelong elevation in low-density lipoprotein cholesterol (LDL-C) concentration, and very high risk of premature cardiovascular disease (CVD). 2 Because the physical signs of FH manifest later in life, establishing an early diagnosis can be challenging.
FH is a genetic condition, most commonly caused by a mutation in the LDL receptor gene, with variable resultant clinical phenotype. The most common form is heterozygous FH (HeFH); homozygous FH (HoFH) is rare severe form affecting approximately 1 in 1,000,000 individuals.
Early identification and treatment are critical; however, a lack of awareness in primary care means much FH remains undiagnosed, despite the greatly elevated CVD risk. 1, 2 
Clinical manifestations of FH and CVD risk
In HeFH, CVD typically develops before the age of 55 years in men and before the age of 60 years in women, while in HoFH, CVD manifests very early in life, usually before the age of 20 years. 3 If left untreated, just around half of all individuals with HeFH will survive to the age of 60 years. 4 Most people with FH are asymptomatic until complications of untreated high cholesterol manifest. Rarely, patients may have visible signs of extremely high cholesterol, such as tendon xanthomata (cholesterol deposits in the tendons), xanthelasma (cholesterol deposits under the skin, usually around the eyelids; see Figure 1 ) or corneal arcus (a white or grey ring or arc around the cornea).
If FH is suspected, cardiovascular risk stratification algorithms (eg QRISK2), which are based on the general population,
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Diagnosis of FH
As a simple guide, FH should be suspected in individuals with LDL-C concentrations >5mmol/L, total cholesterol (TC) concentrations >7.5mmol/L and/or a family history of premature CVD.
FH is diagnosed on phenotypic criteria, eg an elevated LDL-C concentration plus a family history of elevated LDL-C or premature CHD, and/or a genetic diagnosis. A provisional diagnosis can be made using one of several validated criteria. NICE recommends using either Simon Broome or Dutch Lipid Clinic Network (DLCN) criteria (see Tables 1 and 2 ) 5 -both of these include lipid values, family history, cardiovascular events in the person and their relatives, and the existence of tendon xanthoma. The FH Score tool (www.fhscore.eu) is a simple online questionnaire version of the DLCN criteria that can be used by anyone to support the diagnosis of HeFH in an adult.
Secondary causes of hypercholesterolaemia, such as hypothyroidism, liver dysfunction, renal dysfunction and diabetes mellitus should be excluded before diagnosing FH.
HoFH should be considered in adults with an LDL-C concentration >13mmol/L and in children/young people with an LDL-C concentration >11mmol/L. 5 All people with a provisional diagnosis of FH should be referred to a lipid clinic that can offer appropriate specialist advice and cascade testing. 5 
Cascade testing
Evidence suggests that if FH is diagnosed early and treated properly, affected individuals can achieve a normal life expectancy. 3 Cascade screening of family members of a known index case, usually led by lipid clinics, is the most effective way to identify new cases. 3 As FH is an autosomal dominant condition, 50% of first-degree relatives of FH cases will also be affected, so screening family members provides a valuable opportunity to diagnose and treat these individuals before they develop CVD.
Management of FH
FH is treatable with LDL-C lowering strategies, which include lifestyle modifications, pharmacotherapy and, in extreme cases, lipid apheresis. Early treatment of FH is highly beneficial in reducing CVD events, 4 particularly in individuals with severe FH or a family history of premature CVD.
Lifestyle modifications
Establishing a healthy lifestyle is very important. NICE guidelines recommend a combination of a healthy diet, physical exercise, weight control, blood pressure control, reduced alcohol intake and smoking cessation. 5 
Pharmacotherapy
The current NICE goal of treatment in adults with FH is a ≥50% decrease in LDL-C concentrations, 5 which requires aggressive lipid lowering. The European Society of Cardiology/European Atherosclerosis Society (ESC/EAS) guidelines go further in rec-ommending target LDL-C concentrations of <2.5mmol/L, or <1.8mmol/l if CVD already evident. 4 Statins are the recommended first-line treatment for all adults with FH. 5 Ezetimibe is recommended in adults with FH as monotherapy if statin intolerant or if a statin is contraindicated, or in combination with a statin if lipid control is inadequate with statins alone.
Although guidelines recommend aggressive LDL-C reduction, many patients with FH cannot reach their target LDL-C goal using conventional pharmacotherapy. The PCSK9 inhibitors, alirocumab and evolocumab, both licensed for use in the UK and approved by NICE in certain high-risk populations (TA393 and TA394), 6, 7 are subcutaneously injected, novel lipid-lowering agents that may address this unmet medical need. These drugs bind to plasma proprotein convertase subtilisin/kexin type 9 (PCSK9) and reduce the endosomal degradation of LDL receptors. They have been shown in wide-ranging clinical trial programmes to reduce LDL-C by approximately an additional 60% when prescribed in combination with standard lipid-lowering agents and are well tolerated. 8
Educational needs of people with FH
People with FH will require lifelong treatment. It is therefore essential that they are provided with written information about the condition, including its genetic basis and inheritance, the process of cascade testing, DNA testing and the measurement 
Conclusion
FH should be strongly suspected in any person with high LDL-C and a family history of premature CVD. The earlier an FH diagnosis can be made, the better, as this will benefit not just the patient, but also potentially their extended family.
Statins are an effective first-line therapy and can be combined with other agents for improved lipid control. However, some patients remain at high CV risk, either because they cannot tolerate statins or do not achieve adequate control. Novel therapies, such as the PCSK9 inhibitors, can help to address this unmet need.
Free tools and advice are available to aid the identification of FH in primary care (see Resources below). Once a provisional diagnosis of FH is made, refer to your local lipid specialist/clinic for confirmation, cascade screening and expert support.
Resources
Public Health England. 
